secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2025-04-14T23:59:59+00:00
Accession:  0001193125-25-080185
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres Therapeutics stockholders approve 1-for-20 reverse stock split, 2025 Incentive Plan
--------------------------------------------------------------------------------

- Reverse stock split at 1-for-20 ratio approved; effective April 21, 2025; trading on split-adjusted basis April 22 under symbol MCRB.
- 2025 Incentive Award Plan authorized 44,604,870 shares for future awards, amending and restating the 2015 Plan.
- Three Class I directors elected: Dennis A. Ausiello, M.D.; Willard H. Dere, M.D.; Eric D. Shaff.
- Advisory say-on-pay vote passed with 57.9M for vs 32.5M against.
- Proposals to amend certificate to eliminate supermajority voting and clarify share authorization did not pass.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312525080185/0001193125-25-080185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312525080185/d935169d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-080185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer